Breast Cancer | Specialty

Developments With Immunotherapy, Maintenance Therapy, and Novel Strategies Push the Field of Women’s Cancers Forward

January 6th 2022

Melissa Geller, MD, MS, and colleagues discuss key clinical trials that have changed the landscapes of HER2-positive breast cancer and triple-negative breast cancer, the role of first- and second-line maintenance therapy in ovarian cancer, and key updates in cervical and endometrial cancers.

Aggarwal Shines a Light on Precision Medicine in Lung, Breast, Ovarian, and GI Cancers

January 6th 2022

Molecular testing is an established and essential precursor to treatment for patients with non–small cell lung cancer based on the volume of actionable targets, such as EGFR and KRAS G12C mutations, as well as PD-L1 status.

Dr. Brufsky on the Efficacy of Enobosarm in ER+/AR+ Breast Cancer

January 5th 2022

Adam M. Brufsky, MD, PhD, FACP, discusses efficacy data with enobosarm in metastatic estrogen receptor–positive, androgen receptor–positive, HER2-negative breast cancer.

Dr. Tolaney on the Importance of Evaluating Enobosarm in ER+ Breast Cancer

January 5th 2022

Sara M. Tolaney, MD, MPH, chief, discusses the importance of evaluating enobosarm in metastatic estrogen receptor–positive, HER2-negative breast cancer.

Applications of FES-PET Imaging in Breast Cancer Treatment Decision-Making

January 5th 2022

Expert perspective on the applications of FES-PET imaging in treatment decision-making in patients with breast cancer.

Role of FDG-PET Vs FES-PET in ER+ Breast Cancer

January 5th 2022

Dr Gary Ulaner compares the role of FDG-PET and FES-PET imaging in ER+ Breast Cancer and the ability of each of the 2 techniques in assessing ER status.

Bardia on Sacituzumab Govitecan’s Current and Potential Future Position in TNBC

December 30th 2021

Dr Bardia discusses the role of sacituzumab govitecan in the treatment of patients with metastatic triple-negative breast cancer, the influence of the National Comprehensive Cancer Network guidelines on treatment recommendations and sequencing in the second-line setting, and ongoing research with the agent in the neoadjuvant setting.

Practice-Changing Data From 2021 Sets Tone for New Year

December 29th 2021

Throughout 2021, investigators of several pivotal trials presented findings that may result in shifting standards for the treatment of patients across tumor types.

Abemaciclib Becomes First Agent of its Kind Approved for Adjuvant Treatment of Early Breast Cancer

December 28th 2021

Stephen Johnston, MD, PhD, provides insight on the effect the approval of the CDK4/6 inhibitor abemaciclib has for patients with early breast cancer and how it will advance investigative efforts in this space.

Pembrolizumab Combination Advances Standard of Care in TNBC

December 27th 2021

Peter Schmid, MD, PhD, discussed how this approval defines a new standard of care for patients with TNBC.

Coming Soon, HER2-Positive Breast Cancer: A Review of Data from the SABCS 2021 Virtual Meeting

December 23rd 2021

Virginia Kaklamani, MD, DSc, shares her excitement for an upcoming OncLive® "The TALK" program focusing on HER2-positive breast cancer updates from the SABCS 2021 Virtual Meeting.

Overview of Estrogen Receptor-Targeted Imaging

December 22nd 2021

Experts provide an overview of the imaging modalities that can detect estrogen receptor status in patients with breast cancer.

ER-Positive Breast Cancer and ER Testing Strategies

December 22nd 2021

Gary Ulaner, MD, PhD and Jeremy Force, DO review estrogen receptor (ER)-positive breast cancer and the various strategies available for diagnosing estrogen receptor (ER)-positive breast cancer.

Schwartzberg on Bringing Seminal Observations on AR From Bench to Bedside in ER+ Breast Cancer

December 20th 2021

Dr. Schwartzberg discusses the rationale to evaluate enobosarm in androgen receptor-positive, estrogen recepetor-positive advanced breast cancer, phase 2 data with the agent, and expectations for the ongoing phase 3 ARTEST trial in this population.

Leading Mass General Breast Surgeon Dr. Suzanne Coopey Joins AHN Cancer Institute

December 20th 2021

Breast surgeon Suzanne B. Coopey, MD, FACS, has joined Allegheny Health Network Cancer Institute, where she will serve as Director of the Breast Program at the soon-to-open AHN Wexford Hospital.

Coming Soon: THE TALK: Breast Cancer, A Review of Data from the SABCS 2021 Virtual Meeting

December 20th 2021

Investigators Parse a Crowded Third Line in Relapsed HER2-Positive Metastatic Breast Cancer

December 20th 2021

A panel of breast cancer experts shared their insights on 4 recently approved targeted therapies for patients with relapsed HER2-positive metastatic breast cancer.

Radical Sentinel Lymph Node and Axillary Lymph Node Dissection Can Negatively Affect Outcomes in Patients With Early-Stage Breast Cancer

December 16th 2021

Data presented from the INSEMA trial during the 2021 San Antonio Breast Cancer Symposium indicated that patients with early-stage breast cancer had better quality of life outcomes when forgoing a sentinel lymph node biopsy and axillary lymph node dissection. However, patients had improved arm symptoms and functioning with SLNB vs ALND.

Neratinib Combos Show Promise in HER2-Mutant Metastatic Breast Cancers

December 10th 2021

Neratinib (Nerlynx) induced positive overall response rates in patients with heavily pretreated hormone receptor–positive/HER2-negative, HER2-mutant metastatic breast cancer when combined with fulvestrant and trastuzumab, and also in patients with metastatic HER2-mutant triple-negative breast cancer when combined with trastuzumab.

Dr. Bardia on the Efficacy Results of the EMERALD Trial in ER+/HER2- Breast Cancer

December 10th 2021

Aditya Bardia, MD, MPH, discusses the efficacy results of the phase 3 EMERALD trial in estrogen receptor–positive, HER2-negative metastatic breast cancer.